DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine | DEA.gov
Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

United States Drug Enforcement Administration

  • Get Updates
  • Scam Alert
  • Full Menu
  • English
  • Español

Main Menu

Explore DEA
  • Who We Are
    • About
    • Mission
    • History
    • Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Education and Prevention
    • Drug Information
    • News
    • Campaigns
  • Careers
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
    • FOIA
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
  • Submit A Tip

DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine

WASHINGTON - The U.S. Drug Enforcement Administration is warning the American public of a sharp increase in the trafficking of fentanyl mixed with xylazine. Xylazine, also known as “Tranq,” is a powerful sedative that the U.S. Food and Drug Administration has approved for veterinary use.  

“Xylazine is making the deadliest drug threat our country has ever faced, fentanyl, even deadlier,” said Administrator Milgram. “DEA has seized xylazine and fentanyl mixtures in 48 of 50 States. The DEA Laboratory System is reporting that in 2022 approximately 23% of fentanyl powder and 7% of fentanyl pills seized by the DEA contained xylazine.”

Xylazine and fentanyl drug mixtures place users at a higher risk of suffering a fatal drug poisoning. Because xylazine is not an opioid, naloxone (Narcan) does not reverse its effects. Still, experts always recommend administering naloxone if someone might be suffering a drug poisoning. People who inject drug mixtures containing xylazine also can develop severe wounds, including necrosis—the rotting of human tissue—that may lead to amputation.

According to the CDC, 107,735 Americans died between August 2021 and August 2022 from drug poisonings, with 66 percent of those deaths involving synthetic opioids like fentanyl. The Sinaloa Cartel and Jalisco Cartel in Mexico, using chemicals largely sourced from China, are primarily responsible for the vast majority of the fentanyl that is being trafficked in communities across the United States.

FDA recently communicated to health care providers about the risks to patients exposed to xylazine in illicit drugs. A copy of that communication can be found here: FDA alerts healthcare professionals of risks to patients exposed to xylazine in illicit drugs.

 

###

 

The DEA issues Public Safety Alerts to warn the public of new, emerging threats to the safety and health of the American people. The DEA last issued a Public Safety Alert in September 2021 warning the public about increases in the lethality and availability of fentanyl-laced fake prescription pills. The DEA updated that alert in November 2022 warning that six out of ten fentanyl-laced fake prescription pills contain a potentially lethal dose of fentanyl.

 

 

SAMHSA Behavioral Health Treatment Locator

  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Drug Prevention
    • Diversion Control Division
    • News
  • Careers
    • Special Agent
    • Diversion Investigator
    • Forensic Sciences
    • Intelligence Research Specialist
    • How to Apply
  • Resources
    • Drug Information
    • Employee Assistance Program
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
    • Vendor Engagement Request
  • Policies
    • Accessibility & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster

United States Drug Enforcement Administration

Back
  • Who We Are
  • What We Do
  • Careers
  • Resources
Back
  • About
  • Mission
  • History
  • Divisions
  • DEA Museum
  • Wall of Honor
  • Contact Us
Back
  • Domestic Divisions
  • Foreign Divisions
  • Operational Divisions
Back
  • Submit a Tip
  • Extortion Scam
  • Public Affairs
  • Social Media Directory
Back
  • Forensic Sciences
  • Law Enforcement
  • Education and Prevention
  • Drug Information
  • News
  • Campaigns
Back
  • GUARDS
  • Forensic Sciences Policy
  • Forensic Science Organizations
  • Forensic Science Contact
Back
  • DEA Office of Training
  • El Paso Intelligence Center (EPIC)
  • Intelligence
  • Operations
Back
  • Office of Training Programs
Back
  • Administrative Law Judges
  • DEA Asset Forfeiture
  • Domestic Cannabis Suppression / Eradication Program
  • HIDTA
  • OCDETF
Back
  • Family Summit
  • Red Ribbon
  • Kiki and the History of Red Ribbon Week
  • Red Ribbon Toolkit - Resources For Your Community
  • DEA’s Family Summit
  • Operation Engage
  • Community Outreach
  • Just Think Twice
  • Campus Drug Prevention
  • Get Smart About Drugs
  • Operation Prevention
Back
  • Drug Policy
  • Drug Scheduling
  • The Controlled Substances Act
Back
  • Alerts
  • Press Releases
  • Most Wanted Fugitives
  • Stories
  • Events
  • Speeches
  • Testimony
Back
  • All Fugitives
Back
  • One Pill Can Kill
  • DEA National Prescription Drug Take Back Day
Back
  • Senior Citizens
  • Partner Toolbox
  • Social Media Campaign
Back
  • Special Agent
  • Diversion Investigator
  • Intelligence Research Specialist
  • Forensic Sciences Careers
  • Professional & Administrative Careers
  • Student & Entry Level Careers
  • Employment Eligibility
  • How to Apply
Back
  • Special Agent FAQs
Back
  • Diversion Investigator Job Announcement
Back
  • Intelligence Research Specialist Job Announcements
  • Intelligence Research Specialists FAQs
  • Schedule A Hiring Authority: Intelligence Research Specialist
Back
  • How To Claim Veterans' Preference
  • Priority Consideration
  • Benefits
  • Veterans and People With Disabilities
  • Operation Warfighter
Back
  • Illegal Online Pharmacies
  • OD Justice
  • Fentanyl Supply Chain
  • Pill Press Resources
  • Recovery Resources
  • Together for Families
  • Data and Statistics
  • FOIA
  • Publications
  • Media Galleries
  • Victim Witness Assistance Program
Back
  • Domestic Arrests
  • Staffing and Budget
Back
  • About FOIA
  • Contact DEA FOIA
  • Make a Request
  • What Happens After Making a Request
  • Requester Categories
  • Fees Charged
  • Fee Waiver
  • FOIA FAQ
  • FOIA Logs and Reports
  • FOIA Library
  • Additional FOIA Links
  • FOIA Exemptions
  • What Are Exclusions?
  • Privacy Act
  • Privacy Act Exemptions
  • Privacy Impact Assessment and Management Information Systems
Back
  • Victim Witness Assistance Program Resources
  • Human Trafficking Prevention
  • Submit A Tip +
  • Get Updates
  • Scam Alert
    • English
    • Español